Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

August 2, 2024

https://www.globenewswire.com/news-release/2024/08/01/2922770/0/en/Corvus-Pharmaceuticals-Granted-FDA-Fast-Track-Designation-for-Soquelitinib-for-Treatment-of-Patients-with-Relapsed-or-Refractory-Peripheral-T-cell-Lymphoma-PTCL.html

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024

Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.